Aptevo Therapeutics files prospectus supplement for up to $2.3 million in at-the-market share sales
Aptevo Therapeutics filed a prospectus supplement under its existing Form S-3 shelf registration covering up to $2,309,834 of common stock to be sold through an at-the-market program with Roth Capital Partners. The company said it had previously sold 303,157 shares for gross proceeds of $11.8 million under the same agreement, so new sales could dilute existing shareholders.
Key points
- Offering of up to $2,309,834 in common stock under the April 28, 2025 At The Market Offering Agreement with Roth Capital Partners, LLC
- Prior sales under the agreement: 303,157 shares for aggregate gross proceeds of $11.8 million
- Paul Hastings LLP issued a legal opinion on the shares, filed as Exhibit 5.1
- Filing dated October 30, 2026; 8-K signed November 2, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.